MedTrace Logo

Rwanda Selenium Supplementation Clinical Trial

NCT01327755 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2013-10-29

No results posted yet for this study

Summary

Study Hypothesis: The addition of selenium supplementation to cotrimoxazole will improve CD4 counts, decrease opportunistic infections, decrease viral loads and delay the need for initiating antiretroviral therapy(ART) in Rwandan adult patients infected with HIV/ AIDS.

Conditions

Interventions

DIETARY_SUPPLEMENT

Selenium

Selenium yeast containing selenomethionine 200 mcg per day for 2 years

OTHER

Placebo

Same number of pills, frequency, and duration as selenium intervention.

Sponsors & Collaborators

  • Global Benefit Canada

    collaborator UNKNOWN

  • University of Ottawa

    collaborator OTHER

  • Wilfrid Laurier University

    collaborator OTHER

  • Kibagabaga District Hospital

    collaborator UNKNOWN

  • Kinyinya Health Centre

    collaborator UNKNOWN

  • The Canadian College of Naturopathic Medicine

    lead OTHER

Principal Investigators

  • Julius K Kamwesiga, MD MPH(cand) · Rwanda Selenium Supplementation Clinical Trial

  • Don Warren, BSc ND DHANP · Global Benefit Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • Rwanda

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01327755 on ClinicalTrials.gov